[HTML][HTML] Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
S Mitsunaga, M Ikeda, S Shimizu, I Ohno… - British journal of …, 2013 - nature.com
S Mitsunaga, M Ikeda, S Shimizu, I Ohno, J Furuse, M Inagaki, S Higashi, H Kato, K Terao…
British journal of cancer, 2013•nature.comBackground: With this study, we sought to characterise the impact of pro-inflammatory
cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic
cancer (PC). Methods: Treatment-naive patients with advanced PC and no obvious
infections were eligible for enrolment. All of the patients were scheduled to undergo
systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-
chemiluminescence assay method before chemotherapy. High cytokine levels were defined …
cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic
cancer (PC). Methods: Treatment-naive patients with advanced PC and no obvious
infections were eligible for enrolment. All of the patients were scheduled to undergo
systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-
chemiluminescence assay method before chemotherapy. High cytokine levels were defined …
Abstract
Background:
With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC).
Methods:
Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of the patients were scheduled to undergo systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-chemiluminescence assay method before chemotherapy. High cytokine levels were defined as values greater than the median. Clinical data were collected prospectively.
Results:
Sixty patients who received GEM were included in the analysis. High IL-6 and IL-1β levels were poor prognostic factors for overall survival in a multivariate analysis (P= 0.011 and P= 0.048, respectively). Patients with both a high IL-6 level and a high IL-1β level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1β.
Conclusion:
The serum levels of IL-6 and IL-1β predict the efficacy of GEM in patients with advanced PC.
nature.com